Cell cycle phase distribution analysis in chronic lymphocytic leukaemia: A significant number of cells reside in early G1-phase

Journal of Clinical Pathology

Volumn 60, Issue 7, 2007, Pages 794-797

  Obermann, Ellen C ^a   Went, Philip ^b   Tzankov, Alexandar ^c   Pileri, Stefano A ^d   Hofstaedter, Ferdinand ^a   Marienhagen, Joerg ^a   Stoehr, Robert ^a   Dirnhofer, Stephan ^b  

^a UNIVERSITY OF REGENSBURG   (Germany)

^b UNIVERSITY HOSPITAL BASEL   (Switzerland)

^c UNIVERSITY OF INNSBRUCK   (Austria)

^d UNIVERSITY OF BOLOGNA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLIN A; CYCLIN B1; CYCLIN E; MINICHROMOSOME MAINTENANCE PROTEIN 2;

ADULT; AGED; ALGORITHM; ARTICLE; CELL CYCLE G1 PHASE; CELL CYCLE G2 PHASE; CELL CYCLE M PHASE; CELL CYCLE S PHASE; CELL PROLIFERATION; CELL SUBPOPULATION; CHRONIC LYMPHATIC LEUKEMIA; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL;

ADULT; AGED; AGED, 80 AND OVER; CELL CYCLE; CELL CYCLE PROTEINS; CELL PROLIFERATION; CYCLINS; FEMALE; G1 PHASE; HUMANS; IMMUNOENZYME TECHNIQUES; KI-67 ANTIGEN; LEUKEMIA, LYMPHOCYTIC, CHRONIC; MALE; MIDDLE AGED; NEOPLASM PROTEINS; NUCLEAR PROTEINS; PROTEIN ARRAY ANALYSIS;

EID: 34249713823     PISSN: 00219746     EISSN: None     Source Type: Journal    
DOI: 10.1136/jcp.2006.040956     Document Type: Article

References (35)

1. Redaelli A, Laskin BL, Stephens JM, et al. The clinical and epidemiological burden of chronic lymphocytic leukaemia. Eur J Cancer Care 2004;13:279-87.
2. Gentile M, Mauro FR, Guarini A, et al. New developments in the diagnosis, prognosis and treatment of chronic lymphocytic leukemia. Curr Opin Oncol 2005;17:597-604.
3. Blow JJ, Hodgson B. Replication licensing-defining the proliferative state? Trends Cell Biol 2002;12:72-8.
4. Todorov IT, Werness BA, Wang HQ, et al. HsMCM2/BM28: a novel proliferation marker for human tumors and normal tissues. Lab Invest 1998;78:73-8.
5. Burger PC, Shibata T, Kleihues P. The use of the monoclonal antibody Ki-67 in the identification of proliferating cells: application to surgical neuropathology. Am J Surg Pathol 1986;10:611-17.
6. Brown DC, Gatter KC. Ki67 protein: the immaculate deception? Histopathology 2002;40:2-11.
7. Scott IS, Morris LS, Bird K, et al. A novel immunohistochemical method to estimate cell-cycle phase distribution in archival tissue: implications for the prediction of outcome in colorectal cancer. J Pathol 2003;201:187-97.
8. Williams GH, Romanowski P, Morris L, et al. Improved cervical smear assessment using antibodies against proteins that regulate DNA replication. Proc Natl Acad Sci USA 1998;95:14932-7.
9. Freeman A, Morris LS, Mills AD, et al. Minichromosome maintenance proteins as biological markers of dysplasia and malignancy. Clin Cancer Res 1999;5:2121-32.
10. Chatrath P, Scott IS, Morris LS, et al. Aberrant expression of minichromosome maintenance protein-2 and Ki67 in laryngeal squamous epithelial lesions. Br J Cancer 2003;89:1048-54.
11. Xue WC, Khoo US, Ngan HY, et al. Minichromosome maintenance protein 7 expression in gestational trophoblastic disease: correlation with Ki67, PCNA and clinicopathological parameters. Histopathology 2003;43:485-90.
12. Musahl C, Holthoff HP, Lesch R, et al. Stability of the replicative Mcm3 protein in proliferating and differentiating human cells. Exp Cell Res 1998;241:260-4.
13. Stoeber K, Tlsty TD, Happerfield L, et al. DNA replication licensing and human cell proliferation. J Cell Sci 2001;114(Pt 11):2027-41.
14. Lea NC, Orr SJ, Stoeber K, et al. Commitment point during G0-→G1 that controls entry into the cell cycle. Mol Cell Biol 2003;23:2351-61.
15. Hunter T, Pines J. Cyclins and cancer. Cell 1991;66:1071-4.
16. Koff A, Cross F, Fisher A, et al. Human cyclin E, a new cyclin that interacts with two members of the CDC2 gene family. Cell 1991;66:1217-28.
17. Pines J, Hunter T. Cyclins A and B1 in the human cell cycle. Ciba Found Symp 1992;170:187-96.
18. Nasmyth K. Viewpoint: purling the cell cycle in order. Science 1996;274:1643-5.
19. Wolowiec D, Ciszak L, Kosmaczewska A, et al. Cell cycle regulatory proteins and apoptosis in B-cell chronic lymphocytic leukemia. Haematologica 2001;86:1296-304.
20. Delmer A, Ajchenbaum-Cymbalista F, Tang R, et al. Overexpression of cyclin D2 in chronic B-cell malignancies. Blood 1995;85:2870-76.
21. Heidebrecht HJ, Buck F, Endl E, et al. Ki-Mcm6, a new monoclonal antibody specific to Mcm6: comparison of the distribution profile of Mcm6 and the Ki-67 antigen. Lab Invest 2001;81:1163-5.
22. Tzankov A, Pehrs AC, Zimpfer A, et al. Prognostic significance of CD44 expression in diffuse large B cell lymphoma of activated and germinal centre B cell-like types: a tissue microarray analysis of 90 cases. J Clin Pathol 2003;56:747-52.
23. Mueller-Hermelink HK, Montserrat E, Cytovsky D, et al. Chronic lymphocytic leukaemia/small lymphocytic lymphoma. In: Jaffe ES, Harris NL, Stein H, Vardiman JW, eds. Tumours of haematopoietic and lymphoid tissue. Lyon: IARC Press, 2001:127-30.
24. Scott IS, Heath TM, Morris LS, et al. A novel immunohistochemical method for estimating cell cycle phase distribution in ovarian serous neoplasms: implications for the histoparhological assessment of paraffin-embedded specimens. Br J Cancer 2004;90:1583-90.
25. Obermann EC, Eward KL, Dogan A, et al. DNA replication licensing in peripheral B-cell lymphoma. J Pathol 2005;205:318-28.
26. Obermann EC, Went P, Pehrs AC, et al. Cyclin B1 expression is an independent prognostic marker for poor outcome in diffuse large B-cell lymphoma. Oncol Rep 2005;14:1461-7.
27. Jin YH, Park CK. Expression of cyclin B1 and cdc2 in nodal non-Hodgkin's lymphoma and its prognostic implications. J Korean Med Sci 2002;17:322-7.
28. Schraml P, Bucher C, Bissig H, et al. Cyclin E overexpression and amplification in human tumours. J Pathol 2003;200:375-82.
29. Tzankov A, Zimpfer A, Pehrs AC, et al. Expression of B-cell markers in classical Hodgkin lymphoma: a tissue microarray analysis of 330 cases. Mod Pathol 2003;16:1141-7.
30. Went P, Delias T, Bourgau C, et al. Expression profile and prognostic significance of CD24, p53 and p21 in lymphomas. A tissue microarray study of over 600 non-Hodgkin lymphomas. Dtsch Med Wochenschr 2004;129:2094-9.
31. Decker T, Schneller F, Hipp S, et al. Cell cycle progression of chronic lymphocytic leukemia cells is controlled by cyclin D2, cyclin D3, cyclin-dependent kinase (cdk) 4 and the cdk inhibitor p27. Leukemia 2002;16:327-34.
32. Mochen C, Giardini R, Costa A, et al. MIB-1 and S-phase cell fraction predict survival in non-Hodgkin's lymphomas. Cell Prolif 1997;30:37-47.
33. Brons PP, Raemaekers JM, Bogman MJ, et al. Cell cycle kinetics in malignant lymphoma studied with in vivo iododeoxyuridine administration, nuclear Ki-67 staining, and flow cytometry. Blood 1992;80:2336-43.
34. Senderowicz AM, Sausvilie EA. Preclinical and clinical development of cyclin-dependent kinase modulators. J Natl Cancer Inst 2000;92:376-87.
35. Tan AR, Headlee D, Messmann R, et al. Phase I clinical and pharmacokinetic study of flavopiridol administered as a daily 1 -hour infusion in patients with advanced neoplasms. J Clin Oncol 2002;20:4074-82.